Intelligence Graph
Map who decides, what depends on what, and where change propagates.
Institutions, programs, products, standards, payment pathways and evidence infrastructure are represented as connected decision objects—not isolated news items.
Accessible relationship table
| From | Relationship | To | Type | Decision impact |
|---|---|---|---|---|
| CMS Innovation Center | operates | ACCESS Model | Explicit | Defines payment/adoption pathway |
| FDA CDRH | operates | TEMPO | Explicit | Defines TEMPO selection/evidence rules |
| TEMPO | includes | Dexcom Glucose Health Program | Explicit | Dexcom in pilot |
| TEMPO | includes | Cadence HypertensionOS | Explicit | Cadence in pilot |
| ACCESS Model | creates payment context for | TEMPO | Explicit linkage | Regulation-payment convergence |
| ACCESS Model | feeds distribution opportunity into | Medicare App Library | Inferred | ACCESS can reduce distribution friction |
| CMS Aligned Networks | provides data connectivity to | Medicare App Library | Explicit | Enables patient-facing apps |
| ASTP/ONC | advances standardization through | USCDI v6 | Explicit | Expands machine-readable health data |
| HTI-5 | could expand automated data access for | Conversational AI Assistants | Inferred from proposal | Could enable more agentic data access |
| FDA CDER | supports | FDA DHT Drug Development Program | Explicit | Builds DHT evidence methods |
| FDA CDER | supports | Real-Time Clinical Trials POC | Explicit | Accelerates trial evidence flow |
| ARPA-H | operates | PROSPR | Explicit | Federal healthspan R&D infrastructure |
| PROSPR | funds | THRIVE | Explicit | Healthspan score development |
| PROSPR | funds | VITAL-H | Explicit | Aging trial/regulatory path |
| PROSPR | funds | GPER agonist project | Explicit | Healthspan therapeutic test |
| ARPA-H | operates | ADVOCATE | Explicit | Moves agentic AI toward clinical autonomy |
| ARPA-H | operates | IGoR | Explicit | Moves AI into experimental orchestration |
| NIA | convenes | Fifth Geroscience Summit | Explicit | May shape geroscience agenda |
| CY 2027 PFS | could change economics of | Remote Patient Monitoring | Explicit proposal | Changes RPM/RTM viability |
| Electronic Prior Authorization | depends on | USCDI v6 | Inferred | Interoperability supports ePA |
| FDA AI-Enabled Medical Device List | provides regulatory landscape for | Conversational AI Assistants | Inferred | Separates regulated AI from general AI |
| Conversational AI Assistants | listed use case in | Medicare App Library | Explicit | Federal app-discovery path |
| Diabetes & Obesity Prevention/Management Apps | listed use case in | Medicare App Library | Explicit | Prevention-focused distribution path |
| P4L | monitors | ACCESS Model | Internal design | Maintains payment/adoption intelligence |
| P4L | monitors | TEMPO | Internal design | Maintains regulatory/RWE intelligence |
| P4L | monitors | PROSPR | Internal design | Maintains healthspan-R&D intelligence |
| P4L | monitors | ADVOCATE | Internal design | Maintains agentic-AI intelligence |
| P4L | monitors | Medicare App Library | Internal design | Maintains digital-health distribution intelligence |